Calvin A. Grant

From Wikipedia, the free encyclopedia

This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2008)

This article may contain improper references to self-published sources. Please help improve this article by removing unreliable sources. A self-published source may only be cited as a primary source in an article about the author or source itself and not as an authority. (June 2008)

Calvin Alexander Grant, MD, is an American ophthalmologist.

Grant was born in 1970 in Washington, D.C., to Jamaican parents, and spent a large amount of his childhood in the Washington Metropolitan Area. At the age of 21 he attended the University of Pennsylvania School of Medicine where he received the Oliver prize for ophthalmological research. His earlier research in gene transfer to the retina using adeno-associated viruses was one of the first. This work was conducted under the Howard Hughes Medical Student Fellowship.

Grant developed the first sustained treatment for ischaemic and non-ischaemic central retinal vein occlusion. His procedure,^{[citation needed]} called revascularization by anastomotic decompression (RAD), allowed for communication between the blocked superficial retinal venous circulation and the open underlying choroidal circulation.^[1]

Additionally, Grant has demonstrated a significant decrease in the number of treatments of anti-vascular endothelial cell growth factors by the addition of bromfenac in the treatment of choroidal neovascular membrane associated with age-related macular degeneration. There was a significant reduction in the number of injections of anti-VEFG agents that were given within a six-month period.^{[2][unreliable source?]}

Grant has also become the first to introduce robotic radiosurgery in the treatment of choroidal melanoma.^[3]

[edit] References